Association of hemoglobin and survival in peritoneal dialysis patients

Miklos Z. Molnar, Rajnish Mehrotra, Uyen Duong, Csaba Kovesdy, Kamyar Kalantar-Zadeh

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background and objectives Interventional trials and some observational studies show target hemoglobin ≤13 g/dl to be associated with higher mortality in erythropoiesis-stimulating agent-treated (ESA-treated) hemodialysis patients; data for peritoneal dialysis (PD) patients are limited. Design, setting, participants, & measurements We tested our hypothesis that higher and lower achieved hemoglobin levels are associated with increased mortality in 9269 ESA-treated PD patients from all DaVita dialysis clinics during the time period July 2001 through June 2006 followed through June 2007 using a time-dependent analysis. Results Lower hemoglobin was associated with significantly higher all-cause mortality in ESA-treated PD patients: with hemoglobin of 11.0 to <12.0 g/dl as reference, the time-dependent adjusted death hazard ratios for hemoglobin levels of 10.0 to <11.0, 9.0 to <10.0, and ≤9.0 g/dl were 1.12 (1.00 to 1.24), 1.30 (1.12 to 1.50), and 1.38 (1.14 to 1.67), respectively. The time-dependent adjusted hazard ratios for cardiovascular death with hemoglobin levels of 10.0 to <11.0, 9.0 to <10.0, and ≤9.0 g/dl were 1.11 (0.93 to 1.32), 1.37 (1.09 to 1.72), and 1.12 (0.79 to 1.57), respectively. The same trend for association of lower hemoglobin level with higher mortality was seen in African-American and non-African American men and women. In contrast, there was no association between higher achieved hemoglobin and all-cause or cardiovascular mortality in ESA-treated PD patients. Conclusions Lower, but not higher, achieved hemoglobin is associated with higher mortality in ESA-treated PD patients. Randomized controlled trials are needed to examine the target hemoglobin level with lowest mortality in PD patients.

Original languageEnglish (US)
Pages (from-to)1973-1981
Number of pages9
JournalClinical Journal of the American Society of Nephrology
Volume6
Issue number8
DOIs
StatePublished - Aug 1 2011

Fingerprint

Peritoneal Dialysis
Hemoglobins
Survival
Mortality
Hematinics
African Americans
Observational Studies
Renal Dialysis
Dialysis
Randomized Controlled Trials

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation

Cite this

Association of hemoglobin and survival in peritoneal dialysis patients. / Molnar, Miklos Z.; Mehrotra, Rajnish; Duong, Uyen; Kovesdy, Csaba; Kalantar-Zadeh, Kamyar.

In: Clinical Journal of the American Society of Nephrology, Vol. 6, No. 8, 01.08.2011, p. 1973-1981.

Research output: Contribution to journalArticle

Molnar, Miklos Z. ; Mehrotra, Rajnish ; Duong, Uyen ; Kovesdy, Csaba ; Kalantar-Zadeh, Kamyar. / Association of hemoglobin and survival in peritoneal dialysis patients. In: Clinical Journal of the American Society of Nephrology. 2011 ; Vol. 6, No. 8. pp. 1973-1981.
@article{2bfd70423b0e49fc8aeb124c2f4ff9f1,
title = "Association of hemoglobin and survival in peritoneal dialysis patients",
abstract = "Background and objectives Interventional trials and some observational studies show target hemoglobin ≤13 g/dl to be associated with higher mortality in erythropoiesis-stimulating agent-treated (ESA-treated) hemodialysis patients; data for peritoneal dialysis (PD) patients are limited. Design, setting, participants, & measurements We tested our hypothesis that higher and lower achieved hemoglobin levels are associated with increased mortality in 9269 ESA-treated PD patients from all DaVita dialysis clinics during the time period July 2001 through June 2006 followed through June 2007 using a time-dependent analysis. Results Lower hemoglobin was associated with significantly higher all-cause mortality in ESA-treated PD patients: with hemoglobin of 11.0 to <12.0 g/dl as reference, the time-dependent adjusted death hazard ratios for hemoglobin levels of 10.0 to <11.0, 9.0 to <10.0, and ≤9.0 g/dl were 1.12 (1.00 to 1.24), 1.30 (1.12 to 1.50), and 1.38 (1.14 to 1.67), respectively. The time-dependent adjusted hazard ratios for cardiovascular death with hemoglobin levels of 10.0 to <11.0, 9.0 to <10.0, and ≤9.0 g/dl were 1.11 (0.93 to 1.32), 1.37 (1.09 to 1.72), and 1.12 (0.79 to 1.57), respectively. The same trend for association of lower hemoglobin level with higher mortality was seen in African-American and non-African American men and women. In contrast, there was no association between higher achieved hemoglobin and all-cause or cardiovascular mortality in ESA-treated PD patients. Conclusions Lower, but not higher, achieved hemoglobin is associated with higher mortality in ESA-treated PD patients. Randomized controlled trials are needed to examine the target hemoglobin level with lowest mortality in PD patients.",
author = "Molnar, {Miklos Z.} and Rajnish Mehrotra and Uyen Duong and Csaba Kovesdy and Kamyar Kalantar-Zadeh",
year = "2011",
month = "8",
day = "1",
doi = "10.2215/CJN.01050211",
language = "English (US)",
volume = "6",
pages = "1973--1981",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "8",

}

TY - JOUR

T1 - Association of hemoglobin and survival in peritoneal dialysis patients

AU - Molnar, Miklos Z.

AU - Mehrotra, Rajnish

AU - Duong, Uyen

AU - Kovesdy, Csaba

AU - Kalantar-Zadeh, Kamyar

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Background and objectives Interventional trials and some observational studies show target hemoglobin ≤13 g/dl to be associated with higher mortality in erythropoiesis-stimulating agent-treated (ESA-treated) hemodialysis patients; data for peritoneal dialysis (PD) patients are limited. Design, setting, participants, & measurements We tested our hypothesis that higher and lower achieved hemoglobin levels are associated with increased mortality in 9269 ESA-treated PD patients from all DaVita dialysis clinics during the time period July 2001 through June 2006 followed through June 2007 using a time-dependent analysis. Results Lower hemoglobin was associated with significantly higher all-cause mortality in ESA-treated PD patients: with hemoglobin of 11.0 to <12.0 g/dl as reference, the time-dependent adjusted death hazard ratios for hemoglobin levels of 10.0 to <11.0, 9.0 to <10.0, and ≤9.0 g/dl were 1.12 (1.00 to 1.24), 1.30 (1.12 to 1.50), and 1.38 (1.14 to 1.67), respectively. The time-dependent adjusted hazard ratios for cardiovascular death with hemoglobin levels of 10.0 to <11.0, 9.0 to <10.0, and ≤9.0 g/dl were 1.11 (0.93 to 1.32), 1.37 (1.09 to 1.72), and 1.12 (0.79 to 1.57), respectively. The same trend for association of lower hemoglobin level with higher mortality was seen in African-American and non-African American men and women. In contrast, there was no association between higher achieved hemoglobin and all-cause or cardiovascular mortality in ESA-treated PD patients. Conclusions Lower, but not higher, achieved hemoglobin is associated with higher mortality in ESA-treated PD patients. Randomized controlled trials are needed to examine the target hemoglobin level with lowest mortality in PD patients.

AB - Background and objectives Interventional trials and some observational studies show target hemoglobin ≤13 g/dl to be associated with higher mortality in erythropoiesis-stimulating agent-treated (ESA-treated) hemodialysis patients; data for peritoneal dialysis (PD) patients are limited. Design, setting, participants, & measurements We tested our hypothesis that higher and lower achieved hemoglobin levels are associated with increased mortality in 9269 ESA-treated PD patients from all DaVita dialysis clinics during the time period July 2001 through June 2006 followed through June 2007 using a time-dependent analysis. Results Lower hemoglobin was associated with significantly higher all-cause mortality in ESA-treated PD patients: with hemoglobin of 11.0 to <12.0 g/dl as reference, the time-dependent adjusted death hazard ratios for hemoglobin levels of 10.0 to <11.0, 9.0 to <10.0, and ≤9.0 g/dl were 1.12 (1.00 to 1.24), 1.30 (1.12 to 1.50), and 1.38 (1.14 to 1.67), respectively. The time-dependent adjusted hazard ratios for cardiovascular death with hemoglobin levels of 10.0 to <11.0, 9.0 to <10.0, and ≤9.0 g/dl were 1.11 (0.93 to 1.32), 1.37 (1.09 to 1.72), and 1.12 (0.79 to 1.57), respectively. The same trend for association of lower hemoglobin level with higher mortality was seen in African-American and non-African American men and women. In contrast, there was no association between higher achieved hemoglobin and all-cause or cardiovascular mortality in ESA-treated PD patients. Conclusions Lower, but not higher, achieved hemoglobin is associated with higher mortality in ESA-treated PD patients. Randomized controlled trials are needed to examine the target hemoglobin level with lowest mortality in PD patients.

UR - http://www.scopus.com/inward/record.url?scp=80051573899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051573899&partnerID=8YFLogxK

U2 - 10.2215/CJN.01050211

DO - 10.2215/CJN.01050211

M3 - Article

VL - 6

SP - 1973

EP - 1981

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 8

ER -